Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
109.35
+4.62 (4.41%)
Sep 18, 2026, 4:00 PM EDT - Market closed
Inhibrx Biosciences Revenue
In the year 2025, Inhibrx Biosciences had annual revenue of $1.30M with 550.00% growth.
Revenue (ttm)
$1.30M
Revenue Growth
+550.00%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
110
Market Cap
1.61B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.30M | 1.10M | 550.00% |
| Dec 31, 2024 | 200.00K | -1.60M | -88.89% |
| Dec 31, 2023 | 1.80M | -392.00K | -17.88% |
| Dec 31, 2022 | 2.19M | -5.04M | -69.69% |
| Dec 31, 2021 | 7.23M | -5.66M | -43.89% |
| Dec 31, 2020 | 12.89M | -323.00K | -2.44% |
| Dec 31, 2019 | 13.21M | 4.62M | 53.71% |
| Dec 31, 2018 | 8.60M | 204.00K | 2.43% |
| Dec 31, 2017 | 8.39M | 1.72M | 25.86% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Innoviva | 440.00M |
| Novavax | 413.80M |
| Syndax Pharmaceuticals | 252.25M |
| AnaptysBio | 232.39M |
| Ascentage Pharma Group International | 94.61M |
| Intellia Therapeutics | 59.51M |
INBX News
- 11 days ago - Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study - Reuters
- 11 days ago - Inhibrx Biosciences Transcript: Study update - Transcripts
- 11 days ago - Inhibrx Biosciences Press release: Study update - Filings
- 11 days ago - Inhibrx Biosciences Slides: Study update - Filings
- 11 days ago - Inhibrx’s INBRX-106 achieves clinical benefit in Phase 2 HNSCC study - TheFly
- 11 days ago - Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study - PRNewsWire
- 15 days ago - Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study - PRNewsWire
- 26 days ago - Inhibrx initiated with a Buy at H.C. Wainwright - TheFly